Novozymes A/S (OTCMKTS:NVZMY) Sees Significant Drop in Short Interest
by Doug Wharley · The Cerbat GemNovozymes A/S (OTCMKTS:NVZMY – Get Free Report) was the recipient of a large decline in short interest in the month of April. As of April 30th, there was short interest totaling 8,733 shares, a decline of 92.9% from the April 15th total of 123,173 shares. Based on an average trading volume of 100,079 shares, the short-interest ratio is presently 0.1 days. Currently, 0.0% of the company’s shares are sold short.
Analyst Ratings Changes
A number of research firms have recently weighed in on NVZMY. Zacks Research downgraded Novozymes A/S from a “hold” rating to a “strong sell” rating in a research note on Monday, May 4th. Rothschild & Co Redburn raised Novozymes A/S to a “strong-buy” rating in a research note on Friday, March 27th. One analyst has rated the stock with a Strong Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, Novozymes A/S has a consensus rating of “Moderate Buy”.
Get Our Latest Stock Report on Novozymes A/S
Novozymes A/S Trading Down 0.9%
OTCMKTS NVZMY traded down $0.54 during trading on Monday, reaching $59.15. 58,628 shares of the stock traded hands, compared to its average volume of 67,214. Novozymes A/S has a fifty-two week low of $49.90 and a fifty-two week high of $75.99. The company has a quick ratio of 0.44, a current ratio of 0.72 and a debt-to-equity ratio of 0.12. The firm has a market cap of $24.52 billion, a price-to-earnings ratio of 39.97, a price-to-earnings-growth ratio of 1.12 and a beta of 0.98. The stock’s 50-day moving average price is $58.31 and its 200 day moving average price is $61.03.
Novozymes A/S (OTCMKTS:NVZMY – Get Free Report) last posted its earnings results on Tuesday, May 5th. The biotechnology company reported $0.51 earnings per share for the quarter, missing the consensus estimate of $0.82 by ($0.31). The firm had revenue of $1.31 billion during the quarter, compared to analyst estimates of $1.32 billion. Novozymes A/S had a return on equity of 6.57% and a net margin of 14.22%. Analysts predict that Novozymes A/S will post 2.43 EPS for the current year.
About Novozymes A/S
Novozymes A/S is a Danish biotechnology company that develops, produces and markets industrial enzymes and microorganisms. Headquartered in Bagsværd, Denmark, the company focuses on using biological solutions to improve industrial processes across a range of end markets. Its offerings are designed to increase product performance or process efficiency while reducing energy, water and chemical consumption for customers.
The company’s product portfolio includes enzymes and microbial solutions for household care (detergents and cleaning products), food and beverages (baking, brewing and dairy applications), bioenergy (enzymes for biofuel production), agriculture (microbial crop inputs and biocontrols) and industrial processing (textiles, pulp and paper, and wastewater treatment).